Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02446600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02446600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 28, 2016
Completion date
March 4, 2027
Enrollment
579 (actual)
Sites
356

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube clear cell adenocarcinoma, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, ovarian clear cell adenocarcinoma, ovarian endometrioid tumor, ovarian seromucinous carcinoma, ovarian serous tumor, ovarian transitional cell carcinoma, ovarian undifferentiated carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent primary peritoneal carcinoma